Pretomanid Tablets and Vistogard

• Generic Name: pretomanid
• Dosage Forms: tablet
• Other Brand Names:

Limited Population: Pretomanid is an antimycobacterial indicated as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients.

Pretomanid is not indicated for patients with: drug-sensitive (DS) tuberculosis, latent infection due to Mycobacterium tuberculosis, extrapulmonary infection due to M. tuberculosis, or MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy.

Safety and effectiveness of pretomanid have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen.

• Generic Name: uridine
• Dosage Forms: oral granules
• Other Brand Names: Vistogard, Xuriden

Vistogard (uridine triacetate) works by slowing down cell damage caused by certain cancer medicines (capecitabine or fluorouracil).

Vistogard is used to treat an overdose of capecitabine or fluorouracil.

Vistogard is also used in an emergency to treat life-threatening side effects caused by capecitabine or fluorouracil. This includes effects on the heart, nervous system, stomach, intestines, or blood cells.

This medicine may be given before overdose symptoms appear. However, treatment with Vistogard must begin within 96 hours after you last received capecitabine or fluorouracil.